Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Bintrafusp alfa (Primary) ; CV 301 (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 16 Feb 2024 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.
- 16 Feb 2024 Planned primary completion date changed from 31 Jan 2024 to 31 Jan 2025.
- 19 Jul 2023 Status changed from recruiting to active, no longer recruiting.